AUDIOCURE-PHARMA
7.12.2023 10:06:33 CET | Business Wire | Press release
AudioCure Pharma GmbH announced today that it has been awarded for its innovative compound AC102 by the Hearing Technology Innovator Awards™, honoring technological innovation and breakthroughs in the hearing industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205308215/en/
Dr. Reimar Schlingensiepen (left, CEO of AudioCure Pharma GmbH) and Prof. Hans Rommelspacher (founder and CSO) receive the award in the therapeutics category. (Photo: AudioCure Pharma)
AudioCure is developing the therapeutic small molecule AC102 to treat hearing impairments including Sudden Sensorineural Hearing Loss (SSNHL). While corticosteroids are the standard treatment, health authorities have never approved them as there is no clear evidence of a clinically relevant benefit to the patient. AudioCure is conducting extensive research to develop targeted and effective therapies to address this high unmet medical need. In preclinical hearing loss models, a single application of AC102 in the middle ear almost completely restores hearing, strongly outperforming multiple doses of corticosteroid therapy. After AC102 was demonstrated as safe and well-tolerated in healthy volunteers, a Europe-wide Phase 2 clinical trial is currently underway evaluating the efficacy of AC102 compared to corticosteroids. Patients with severe to profound SSNHL can be enrolled within 5 days of symptom onset at up to 50 study centers, including in Austria, Germany, The Czech Republic, The Netherlands, Poland and Serbia.
"The Innovator Awards aim to acknowledge the individuals and organizations that transform groundbreaking hearing care concepts into reality," explained Dr. Robert Traynor, member of the 2023 Awards program judge's panel. "Companies like AudioCure are playing a pivotal role in advancing innovation throughout the industry."
Reimar Schlingensiepen, CEO of AudioCure, said: “Receiving the Hearing Technology Innovator Award underscores the urgent need for advanced solutions in treating conditions like SSNHL. It also honors the groundbreaking innovation by our founder, Prof. Hans Rommelspacher. Our ongoing Phase 2 clinical trial represents a significant step towards a transformative solution. This recognition fuels our commitment to redefine the standards-of-care in hearing therapeutics.”
For further information, please visit https://www.audiocure.com/hhtm/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231205308215/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xylem Announces Segment Leadership Appointments30.6.2026 13:30:00 CEST | Press release
Xylem Inc. (NYSE: XYL), a leading global water solutions company, today announced two executive leadership appointments, effective July 1, both reporting to President and Chief Executive Officer Matthew Pine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630087773/en/ Meredith Emmerich has been appointed EVP and President, Measurement and Control Solutions at Xylem. Meredith Emmerich has been appointed EVP and President, Measurement and Control Solutions. Most recently, she served as EVP and President, Applied Water at Xylem. Emmerich joined Xylem in 2024 from Carrier Global Corporation (NYSE: CARR), where she was Vice President of Global Enterprise Solutions and held several senior leadership roles, including leading the Americas Commercial HVAC business and the Global Residential, Light Commercial, and VRF HVAC portfolio. Emmerich succeeds Mike McGann, who will serve as senior advisor to ensure a smooth and orderly tra
Strike Europe Secures Full MiCA Authorization, Unlocking Bitcoin Services Across All 27 EU Member States30.6.2026 13:29:00 CEST | Press release
Strike is now available to millions of customers across the European Union Strike, a leading Bitcoin financial services company, today announced that its European entity, Zap (Strike) Europe Limited, has been authorized as a crypto-asset service provider by the Malta Financial Services Authority (MFSA) under the EU's Markets in Crypto-Assets Regulation (MiCA) and the Malta Markets in Crypto Assets Act (Cap. 647, laws of Malta) to provide crypto-asset services. The license enables millions of Europeans across all 27 EU member states to access Strike's suite of Bitcoin financial services under a single regulatory framework, replacing the patchwork of national regimes that previously governed the market. Strike has served eligible European customers since April 2024. The MFSA authorization makes that presence permanent and EU-wide, and positions the company among a small group of firms to complete the MiCA process to date. "Europe deserves a Bitcoin-only company focused on doing one thing
OpZira, Inc. Welcomes Scott Thielman, PhD, as Vice President of Product Development30.6.2026 13:17:00 CEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced that Scott Thielman, PhD, PE, has joined the company as Vice President of Product Development, effective May 1, 2026. Dr. Thielman brings a unique connection to OpZira’s origins. As Chief Technology Officer of Product Creation Studio, he directed the product development of LumiThera’s Valeda® Light Delivery System - the breakthrough photobiomodulation therapy for dry age-related macular degeneration whose acquisition by Alcon led to the creation of OpZira. His involvement with Valeda gives him firsthand knowledge of the science, clinical vision, and engineering decisions that shaped the technology platform from which OpZira was born. For more than 25 years, Dr. Thielman has directed the development of dozens of FDA-cleared medical devices across ophthalmology, neurostimulation, dermatology, urology, and surgical instrumentation, with partners including Olympus
L&T Technology Services Launches Ainfonix™ 4.0 to Unlock Engineering Intelligence Across Process Industries30.6.2026 12:45:00 CEST | Press release
The enterprise AI platform turns millions of engineering artifacts that run a plant into accurate, decision-ready data, delivering up to 85% extraction accuracy and full, audit-ready traceability L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of Ainfonix™ 4.0, a next-generation Engineering Intelligence platform for process industries. Unveiled at EI Live, LTTS’ flagship event that brings together analysts, industry leaders and engineering experts, Ainfonix™ 4.0 marks an important step in the company’s Enterprise AI and Engineering Intelligence strategy. As industrial enterprises accelerate AI adoption, decades of engineering knowledge remain trapped in fragmented drawings, specifications and technical records across disparate systems. Without trusted and accessible engineering data, organizations struggle to realize the full value of AI, automation and digital transformation
Klick Health Acquires Oxford PharmaGenesis, Bringing Together Unsurpassed Scientific-to-Commercial Capabilities for Life Sciences Clients30.6.2026 12:03:00 CEST | Press release
Bonded by breakthroughs and a laser focus on their people and clients, leading independent agencies join forces to deliver accelerated commercial success through broadened medical affairs and communications, market access, and RWE/HEOR offerings; the most advanced degree holders; expanded global reach; and the best workplace culture around Focused on taking life sciences companies into the future, Klick Health today announced its acquisition of Oxford PharmaGenesis, the market-leading HealthScience communications consultancy renowned for its scientific and medical expertise, as well as value and market access consulting throughout Europe, Asia-Pacific, and North America. Today’s news brings together two of the leading independent agencies in life sciences. With Oxford PharmaGenesis’ expertise across medical affairs and market access, and Klick's strength in commercial strategy, medical, creative, digital, analytics, and experience design, they can deliver an unparalleled scientific-to-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom